Glucocorticoids Induce Bone and Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 Ubiquitin Ligases

Abstract

Glucocorticoid excess, either endogenous with diseases of the adrenal gland, stress, or aging or when administered for immunosuppression, induces bone and muscle loss, leading to osteopenia and sarcopenia. Muscle weakness increases the propensity for falling, which, combined with the lower bone mass, increases the fracture risk. The mechanisms underlying glucocorticoid-induced bone and muscle atrophy are not completely understood. We have demonstrated that the loss of bone and muscle mass, decreased bone formation, and reduced muscle strength, hallmarks of glucocorticoid excess, are accompanied by upregulation in both tissues in vivo of the atrophy-related genes atrogin1, MuRF1, and MUSA1. These are E3 ubiquitin ligases traditionally considered muscle-specific. Glucocorticoids also upregulated atrophy genes in cultured osteoblastic/osteocytic cells, in ex vivo bone organ cultures, and in muscle organ cultures and C2C12 myoblasts/myotubes. Furthermore, glucocorticoids markedly increased the expression of components of the Notch signaling pathway in muscle in vivo, ex vivo, and in vitro. In contrast, glucocorticoids did not increase Notch signaling in bone or bone cells. Moreover, the increased expression of atrophy-related genes in muscle, but not in bone, and the decreased myotube diameter induced by glucocorticoids were prevented by inhibiting Notch signaling. Thus, glucocorticoids activate different mechanisms in bone and muscle that upregulate atrophy-related genes. However, the role of these genes in the effects of glucocorticoids in bone is unknown. Nevertheless, these findings advance our knowledge of the mechanism of action of glucocorticoids in the musculoskeletal system and provide the basis for novel therapies to prevent glucocorticoid-induced atrophy of bone and muscle.

Chaperonin 60 sustains osteoblast autophagy and counteracts glucocorticoid aggravation of osteoporosis by chaperoning RPTOR

“…For example, high concentrations of glucocorticoid disrupt endoplasmic reticulum 4 and deteriorates mitochondrial integrity 5 inducing a burst of reactive oxygen radicals that drastically impedes osteoblast viability. Increased E3 ubiquitin ligase signaling ramps up glucocorticoid-induced osteopenia in mice 6 . The mechanism underlying the glucocorticoid-impaired intracellular homeostasis and organelle machinery in osteoblasts upon glucocorticoid stress has not been well investigated.…”

Local controlled release of corticosteroids extends surgically induced joint instability by inhibiting tissue healing

“…The mechanism behind this discrepancy is difficult to pinpoint but may be explained by species differences in receptor binding (Su et al, 2007) and/or signalling (Young, Yoxall, & Wagner, 1978) or differences in balance between mineralocorticoid and glucocorticoid activities of the drug (Nakabayashi et al, 2001;Tanigawa et al, 2002;Zhu et al, 2000). Glucocorticoids can induce muscle atrophy in rodents at relatively low concentrations (Sato et al, 2017) and hence might elicit weight loss at undetectable systemic concentrations. However, although no systemic side effects were found macroscopically and microscopically 12 weeks after treatment, we cannot exclude a possible toxic effect causing the weight loss in TAA-treated animals.…”

Glucocorticoid-induced osteoporosis: an update

“…Whilst glucocorticoids suppress inflammation and hence should mitigate the adverse effects of inflammation, disease relapse despite therapy is associated with episodes of increased bone resorption. Finally, glucocorticoid excess has adverse effects on muscle mass and function, leading to myopathy and increased risk of falls [ 33 ].…”